HUTCHMED sells 45% equity interest for $608 million to focus on core medicines

From GlobeNewswire: 2025-01-01 05:46:43

HUTCHMED has divested its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited for approximately US$608 million to GP Health Service Capital and Shanghai Pharmaceuticals Holding Co., Ltd. The proceeds will be used to advance HUTCHMED’s pipeline and core innovative medicines business, including antibody-targeted therapy conjugate programs expected to enter clinical trials in the second half of 2025. The company plans to focus on discovering, developing, and commercializing novel therapies for cancer and immunological diseases. HUTCHMED will retain a 5% equity interest in SHPL after the transactions, which are expected to close by the end of the first quarter of 2025.



Read more at GlobeNewswire: HUTCHMED Announces US$608 million Divestment of Non-Core